Actinium Pharmaceuticals provided a Q3 2026 update, highlighting the advancement of its HER3-targeted radiotherapy, ATNM-400. The company cleared the 1.0 µCi/kg dose level in its HERACT-PRO-1 study with no dose-limiting toxicities and initiated the RADIANZ pan-tumor imaging study. With $28.7 million in cash as of September 30, 2026, the company expects to fund operations through 2027.
This is the company's own corporate update: HER3 disclosed as the ATNM-400 target, first HERACT-PRO-1 cohort cleared 1.0 µCi/kg with no dose-limiting toxicities, dose escalation at 1.5 µCi/kg, first RADIANZ patient dosed, and cash of $28.7 million as of September 30, 2026 funding operations through 2027. These are positive pipeline signals, but they are early Phase 1 safety and imaging findings without comparative efficacy figures, so they do not yet change the financial outlook. The stated cash runway through 2027 removes near-term financing pressure but also signals a small-cap burn profile.
- • KOL webinar on ATNM-400 on December 1, 2026, 8:00 a.m. ET
- • SABCS 2026 breast cancer preclinical poster on December 9, 2026
- • Only one cohort cleared at 1.0 µCi/kg with dose escalation still ongoing
- • No efficacy or survival data reported, only imaging uptake through Day 7